Zytoprotec

Executive Summary

Zytoprotec is a Vienna-based biotech focused on improving outcomes for peritoneal dialysis (PD) patients through its innovative dialysate, PDprotec®. Peritoneal dialysis is a common renal replacement therapy, but current PD fluids often lead to complications such as peritoneal membrane damage, infection, and inadequate toxin clearance. PDprotec® is designed to address these limitations by optimizing the fluid composition, potentially enhancing patient survival and quality of life while reducing healthcare costs. With millions of patients worldwide dependent on dialysis, the market need is significant. The company has advanced to Phase 3 clinical trials, indicating promising preclinical and early clinical data. If successful, PDprotec® could become a new standard of care in PD, offering Zytoprotec a substantial commercial opportunity in a growing dialysis market. The company remains private, and its progression through late-stage development will depend on successful trial outcomes and regulatory engagement.

Upcoming Catalysts (preview)

• H2 2026Phase 3 Top-Line Data Readout70% success
• 2027Regulatory Submission (EMA/FDA) for PDprotec®60% success
• 2026Partnership or Licensing Deal with Major Dialysis Provider50% success